Erich Schlick, a venture capitalist and industrialist, has been appointed chair of the board of directors of Switzerland-based NBE-Therapeutics GmbH which is developing antibody-drug conjugates. He is currently a general partner and managing director at Wellington Partners in Munich. Prior to this, he was director and head of 3i Healthcare Germany and earlier in his career, an executive at BASF Pharma/Knoll AG where he was responsible for global preclinical and clinical R&D.
Professor Schlick studied medicine in Germany and trained at the US National Cancer Institute. He holds a professorship in immune pharmacology at the University of Heidelberg, Germany.
NBE-Therapeutics announced the appointment on 10 August 2020.
Copyright 2020 Evernow Publishing Ltd